Sodium oxybate in the treatment of alcohol withdrawal syndrome: A randomized double-blind comparative study versus oxazepam. the gate 1 trial

Fabio Caputo, Katrin Skala, Antonio Mirijello, Anna Ferrulli, Henriette Walter, Otto Lesch, Giovanni Addolorato

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS. Methods: Alcohol-dependent outpatients (n = 126) affected by uncomplicated AWS according to the Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) scale were enrolled in the study and randomized in two groups: 61 patients received SMO and 65 patients received oxazepam for 10 days. The primary endpoint was the reduction of symptoms of AWS measured by the change in the total CIWA-Ar score from baseline (day 1) to the end of the study (day 10). This study is registered with ClinicalTrials.gov, number: NCT02090504 Results: A significant decrease of the mean total CIWA-Ar score from baseline to the end of the study was found in both the SMO (p <0.0001) and the oxazepam group (p <0.0001), with no significant differences between the two treatments (p = 0.21). Treatment with SMO and oxazepam resulted in a marked decrease in the severity of the mean CIWA subscales, i.e. sweating, tremor, and anxiety, with no significant differences between the two treatments. Both drugs were well tolerated and no severe side effects were reported. Conclusion: SMO is as effective as oxazepam, one of the gold standard BDZs, in the treatment of uncomplicated AWS. Due to its tolerability and absence of significant side effects, SMO may be considered a valid alternative choice in the treatment of AWS.

Original languageEnglish
Pages (from-to)743-752
Number of pages10
JournalCNS Drugs
Volume28
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Oxazepam
Sodium Oxybate
Double-Blind Method
Alcohols
Therapeutics
Benzodiazepines
Substance Withdrawal Syndrome
Sweating
Tremor
Outpatients

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Clinical Neurology
  • Medicine(all)

Cite this

Sodium oxybate in the treatment of alcohol withdrawal syndrome : A randomized double-blind comparative study versus oxazepam. the gate 1 trial. / Caputo, Fabio; Skala, Katrin; Mirijello, Antonio; Ferrulli, Anna; Walter, Henriette; Lesch, Otto; Addolorato, Giovanni.

In: CNS Drugs, Vol. 28, No. 8, 2014, p. 743-752.

Research output: Contribution to journalArticle

Caputo, Fabio ; Skala, Katrin ; Mirijello, Antonio ; Ferrulli, Anna ; Walter, Henriette ; Lesch, Otto ; Addolorato, Giovanni. / Sodium oxybate in the treatment of alcohol withdrawal syndrome : A randomized double-blind comparative study versus oxazepam. the gate 1 trial. In: CNS Drugs. 2014 ; Vol. 28, No. 8. pp. 743-752.
@article{a0d11e439dd241fa9456017fcfe435bd,
title = "Sodium oxybate in the treatment of alcohol withdrawal syndrome: A randomized double-blind comparative study versus oxazepam. the gate 1 trial",
abstract = "Background: Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS. Methods: Alcohol-dependent outpatients (n = 126) affected by uncomplicated AWS according to the Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) scale were enrolled in the study and randomized in two groups: 61 patients received SMO and 65 patients received oxazepam for 10 days. The primary endpoint was the reduction of symptoms of AWS measured by the change in the total CIWA-Ar score from baseline (day 1) to the end of the study (day 10). This study is registered with ClinicalTrials.gov, number: NCT02090504 Results: A significant decrease of the mean total CIWA-Ar score from baseline to the end of the study was found in both the SMO (p <0.0001) and the oxazepam group (p <0.0001), with no significant differences between the two treatments (p = 0.21). Treatment with SMO and oxazepam resulted in a marked decrease in the severity of the mean CIWA subscales, i.e. sweating, tremor, and anxiety, with no significant differences between the two treatments. Both drugs were well tolerated and no severe side effects were reported. Conclusion: SMO is as effective as oxazepam, one of the gold standard BDZs, in the treatment of uncomplicated AWS. Due to its tolerability and absence of significant side effects, SMO may be considered a valid alternative choice in the treatment of AWS.",
author = "Fabio Caputo and Katrin Skala and Antonio Mirijello and Anna Ferrulli and Henriette Walter and Otto Lesch and Giovanni Addolorato",
year = "2014",
doi = "10.1007/s40263-014-0183-1",
language = "English",
volume = "28",
pages = "743--752",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "8",

}

TY - JOUR

T1 - Sodium oxybate in the treatment of alcohol withdrawal syndrome

T2 - A randomized double-blind comparative study versus oxazepam. the gate 1 trial

AU - Caputo, Fabio

AU - Skala, Katrin

AU - Mirijello, Antonio

AU - Ferrulli, Anna

AU - Walter, Henriette

AU - Lesch, Otto

AU - Addolorato, Giovanni

PY - 2014

Y1 - 2014

N2 - Background: Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS. Methods: Alcohol-dependent outpatients (n = 126) affected by uncomplicated AWS according to the Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) scale were enrolled in the study and randomized in two groups: 61 patients received SMO and 65 patients received oxazepam for 10 days. The primary endpoint was the reduction of symptoms of AWS measured by the change in the total CIWA-Ar score from baseline (day 1) to the end of the study (day 10). This study is registered with ClinicalTrials.gov, number: NCT02090504 Results: A significant decrease of the mean total CIWA-Ar score from baseline to the end of the study was found in both the SMO (p <0.0001) and the oxazepam group (p <0.0001), with no significant differences between the two treatments (p = 0.21). Treatment with SMO and oxazepam resulted in a marked decrease in the severity of the mean CIWA subscales, i.e. sweating, tremor, and anxiety, with no significant differences between the two treatments. Both drugs were well tolerated and no severe side effects were reported. Conclusion: SMO is as effective as oxazepam, one of the gold standard BDZs, in the treatment of uncomplicated AWS. Due to its tolerability and absence of significant side effects, SMO may be considered a valid alternative choice in the treatment of AWS.

AB - Background: Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS. Methods: Alcohol-dependent outpatients (n = 126) affected by uncomplicated AWS according to the Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) scale were enrolled in the study and randomized in two groups: 61 patients received SMO and 65 patients received oxazepam for 10 days. The primary endpoint was the reduction of symptoms of AWS measured by the change in the total CIWA-Ar score from baseline (day 1) to the end of the study (day 10). This study is registered with ClinicalTrials.gov, number: NCT02090504 Results: A significant decrease of the mean total CIWA-Ar score from baseline to the end of the study was found in both the SMO (p <0.0001) and the oxazepam group (p <0.0001), with no significant differences between the two treatments (p = 0.21). Treatment with SMO and oxazepam resulted in a marked decrease in the severity of the mean CIWA subscales, i.e. sweating, tremor, and anxiety, with no significant differences between the two treatments. Both drugs were well tolerated and no severe side effects were reported. Conclusion: SMO is as effective as oxazepam, one of the gold standard BDZs, in the treatment of uncomplicated AWS. Due to its tolerability and absence of significant side effects, SMO may be considered a valid alternative choice in the treatment of AWS.

UR - http://www.scopus.com/inward/record.url?scp=84905560288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905560288&partnerID=8YFLogxK

U2 - 10.1007/s40263-014-0183-1

DO - 10.1007/s40263-014-0183-1

M3 - Article

C2 - 24996524

AN - SCOPUS:84905560288

VL - 28

SP - 743

EP - 752

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 8

ER -